On July 21, Danaher declined 17.14% in regular trading, trading at $168.86/share, with turnover of $142 million. The selloff was triggered by the company's weak third-quarter growth guidance despite a strong second-quarter earnings beat.

Danaher reported Q2 adjusted EPS of $1.94, exceeding the consensus estimate of $1.83, while revenue of $6.265 billion topped the $6.102 billion estimate, representing 6.8% year-over-year growth. The company also raised its full-year adjusted EPS guidance to $8.45-$8.60, above its prior range of $8.35-$8.55. However, management guided Q3 non-GAAP core revenue growth of only 2.0%-3.0%, a significant deceleration from Q2 levels, which became the primary catalyst for selling pressure.

Multiple institutions recently lowered their price targets, with HSBC cutting to $230 from $270 and Evercore ISI adjusting to $230 from $232. The company also recently completed its approximately $10 billion acquisition of Masimo and announced Leica Biosystems' acquisition of StatLab, with frequent M&A integration raising concerns about near-term financial pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)